< Zurück zu den aktuellen Neuigkeiten & Events

Articles

Protect It Before You Promote It: IP Advice for MedTech Innovators

Oktober 2025

Developed a new medical product? Check.

Got tickets to an exciting MedTech conference to show off your new product? Check.

Intellectual property? Pardon?

In the excitement of bringing a new MedTech product to market it can be easy to overlook or leave intellectual property issues until later. Don’t!

Intellectual property issues are best sorted out upfront and before any greater potential issues arise.

In developing your product, you may want, or need, to give it to focus groups and users to try and test so they can benefit from your product before it goes to market. You’ll need to be able to discuss your product with them and receive their feedback. They will need to be able to use and experience the product to evaluate it. You want to do this in an open and collaborative environment, but without jeopardising your intellectual property rights. This is much easier if it is understood, by everyone involved, what is confidential. Nobody wants to be looking over their shoulder wondering if a previous collaboration or focus group discussion will negatively impact a patent application.  You may worry that conversations about intellectual property ownership are tricky or potentially off putting to those you wish to work with, but issues that feel large at the outset are likely to evaporate on discussion – so be bold and have open, upfront, discussions about confidentiality and ownership so you know what is yours to protect.

The same goes for collaborators. If you identify who owns which aspects of the intellectual property at the start of the relationship and throughout the development process, it will be much easier to address any ownership matters, than having to rake it over and remember who came up with which element. Who wants to have an acrimonious conversation about the legal stuff afterwards, when you really want to get your new medical product out there and helping those who need it? No one.

Furthermore, improperly laying out relationships can result in poor outcomes when trying to protect the product. Can you prove you owns the intellectual property? Is an assignment in place transferring intellectual property to your company? Without a clear legal chain of ownership in place, any patent or design applications may be vulnerable to attack. It may be difficult to show you own an invention and are entitled to file patents for it. Despite how beneficial your new product is to patients, an unproven or unclear chain of ownership may cause your IP protection to fall down on a technicality.

If you are unsure what should be kept secret, what should be protected, or what you can more freely discuss during your product developments and marketing, HGF can help. We are experts in identifying any intellectual property you have, and devising and implementing protection strategies to help you avoid IP pitfalls.

Don’t let intellectual property issues get in the way of marketing and delivering your new medical product to those who need it. Be bold, have conversations up front and ensure you’ve laid the groundwork to make sure you’re protected. Then go and enjoy that conference.


This article was written by Patent Director Frazer Bye.

Aktuelle Neuigkeiten

The Antibody Series #3 | Beitrag Nr. 3: Codenamen von Antikörpern in Ansprüchen: Warum „ACZ885” nicht ausreicht, um den Antikörper zu definieren

          Die Beschwerdekammern des EPA (BoA) sind die Berufungsinstanz, die Entscheidungen des EPA überprüft. In diesem Fall prüften sie einen Anspruch, der einen Antikörper anhand eines …

Weiterlesen

Agritech Thymes: Unlocking the Soil Microbiome: Driving Agritech Innovation in the UK

The UK offers an ideal platform for harnessing the untapped potential of soil and plant microorganisms. Although much of my professional experience has focused on the human microbiome, I have …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen

Oft kopiert, nie erreicht: Wann werden Alltagsgegenstände zum Gegenstand des Urheberrechts?

Die Grenze zwischen „reinen“ Kunstwerken und bloßen Gebrauchsgegenständen – Können ikonische, aber alltägliche Produkte urheberrechtlich geschützt werden? Die obige Frage wurde vom Generalanwalt in den verbundenen Rechtssachen C‑580/23 und C‑795/23 …

Weiterlesen

T 0883/23: Dosierungsansprüche und ihr Anspruch auf Priorität, wenn in der Prioritätsanmeldung nur das Protokoll der klinischen Studie offengelegt wurde

In einer kürzlich ergangenen Entscheidung der Beschwerdekammer (BoA) des EPA entschied die BoA, dass Ansprüche, die auf eine Kombination von pharmazeutischen Wirkstoffen (APIs) in bestimmten Dosen gerichtet sind, keinen Anspruch …

Weiterlesen

Das Ende des Brexit-Überhangs für Marken: Überprüfung, Neuanmeldung und Widerruf.

Am 31. Dezember 2025 sind fünf Jahre seit dem Ende der Brexit-Übergangsperiode am 31. Dezember 2020 vergangen. Warum ist das relevant? Für im Vereinigten Königreich geklonte Markenregistrierungen, die infolge des …

Weiterlesen